Get the Stockscreener App
1.14
0.00%
0.00
After Hours:
1.12
-0.02
-1.75%
Lexicon Pharmaceuticals Inc stock is traded at $1.14, with a volume of 1.17M.
It is up +0.00% in the last 24 hours and down -18.57% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.14
Open:
$1.16
24h Volume:
1.17M
Relative Volume:
0.57
Market Cap:
$414.27M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.425
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-0.87%
1M Performance:
-18.57%
6M Performance:
+26.53%
1Y Performance:
+24.69%
1-Day Range:
$1.12
$1.17
1-Week Range:
$1.11
$1.17
52-Week Range:
$0.2836
$1.66
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.14 | 414.27M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies - Traders Union
How currency fluctuations impact Lexicon Pharmaceuticals Inc. stockWeekly Profit Summary & Stock Portfolio Risk Control - Улправда
FOMO Trade: Can Lexicon Pharmaceuticals Inc. stock continue upward trendQuarterly Investment Review & AI Powered Buy and Sell Recommendations - Улправда
Patterns Watch: Will Lexicon Pharmaceuticals Inc. stock outperform Dow Jones index2025 Fundamental Recap & Smart Allocation Stock Reports - moha.gov.vn
Investment Report: Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekers2025 Buyback Activity & Risk Managed Trade Strategies - Улправда
Aug Catalysts: Is Lexicon Pharmaceuticals Inc. stock resilient to inflation2025 Dividend Review & Advanced Technical Analysis Signals - Улправда
AI Stocks: Can Lexicon Pharmaceuticals Inc. stock beat market expectations this quarterVolume Spike & Real-Time Stock Movement Alerts - Улправда
Why Lexicon Pharmaceuticals Inc. stock is a must watch in 2025July 2025 Patterns & Entry Point Strategy Guides - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock weather global recessionMarket Sentiment Report & Comprehensive Market Scan Reports - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock rebound after recent weaknessWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - DonanımHaber
How Lexicon Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Final Week & AI Optimized Trade Strategies - DonanımHaber
Surprises Report: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsEarnings Growth Report & Daily Oversold Stock Bounce Ideas - Улправда
Is Lexicon Pharmaceuticals Inc. stock resilient to inflation2025 Sector Review & Capital Efficiency Focused Strategies - Улправда
Is Lexicon Pharmaceuticals Inc. stock in correction or buying zone2025 Key Highlights & Real-Time Price Movement Reports - Улправда
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Can Lexicon Pharmaceuticals Inc. stock continue upward trend2025 Key Highlights & High Win Rate Trade Alerts - Улправда
Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money - simplywall.st
Short Covering: How risky is Lexicon Pharmaceuticals Inc stock now2025 Fundamental Recap & Community Verified Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data - Traders Union
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon publishes preclinical data supporting LX9851 obesity treatment - StreetInsider
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 - Yahoo Finance
Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - The Manila Times
Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients - TradingView
Lexicon Pharmaceuticals to Present Clinical Data on Sotagliflozin at CVCT 2025 Conference - Quiver Quantitative
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development - MSN
Is Lexicon Pharmaceuticals Inc. stock attractive for ETFs2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Year in Review: Local co. striking deal worth up to $1B with Ozempic maker was a Deal of the Week - The Business Journals
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha
Piper Sandler Healthcare Conference - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Will Lexicon Pharmaceuticals Inc. stock deliver long term returns2025 Market Overview & Fast Entry High Yield Stock Tips - moha.gov.vn
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences - The Manila Times
Lexicon Pharma (Nasdaq: LXRX) in Piper Sandler 37th and Evercore 8th investor events - Stock Titan
Would You Still Hold Lexicon Pharmaceuticals Stock If It Fell 30%? - Trefis
10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):